Draft Guidance for Industry, Clinical Investigators, Institutional Review Boards, and Staff; Availability: Decisions for Investigational Device Exemption Clinical Investigations

Document ID: FDA-2011-D-0790-0004

Comments

Total: 13
David Forster - Comment
Posted : 02/28/2012     ID :FDA-2011-D-0790-0005     Agency : FDA

Mar 09,2012 11:59 PM ET
Consortium of Independent Review Boards (CIRB) - Comment
Posted : 02/28/2012     ID :FDA-2011-D-0790-0006     Agency : FDA

Mar 09,2012 11:59 PM ET
Cook Group, Inc. - Comment
Posted : 03/14/2012     ID :FDA-2011-D-0790-0007     Agency : FDA

Mar 09,2012 11:59 PM ET
Johnson and Johnson - Comment
Posted : 03/14/2012     ID :FDA-2011-D-0790-0008     Agency : FDA

Mar 09,2012 11:59 PM ET
AstraZeneca - Comment
Posted : 03/14/2012     ID :FDA-2011-D-0790-0009     Agency : FDA

Mar 09,2012 11:59 PM ET
RTI Biologics, Inc - Comment
Posted : 03/14/2012     ID :FDA-2011-D-0790-0010     Agency : FDA

Mar 09,2012 11:59 PM ET
C. R. Bard, Inc. - Comment
Posted : 03/14/2012     ID :FDA-2011-D-0790-0011     Agency : FDA

Mar 09,2012 11:59 PM ET
Medical Imaging & Technology Alliance (MITA) - Comment
Posted : 03/14/2012     ID :FDA-2011-D-0790-0012     Agency : FDA

Mar 09,2012 11:59 PM ET
Merck & Co., Inc. - Comment
Posted : 03/14/2012     ID :FDA-2011-D-0790-0013     Agency : FDA

Mar 09,2012 11:59 PM ET
Association of Clinical Research Professionals (ACRP) - Comment
Posted : 03/14/2012     ID :FDA-2011-D-0790-0014     Agency : FDA

Mar 09,2012 11:59 PM ET
Abbott - Comment
Posted : 03/14/2012     ID :FDA-2011-D-0790-0015     Agency : FDA

Mar 09,2012 11:59 PM ET
The Procter & Gamble Company - Comment
Posted : 03/14/2012     ID :FDA-2011-D-0790-0016     Agency : FDA

Mar 09,2012 11:59 PM ET
Advanced Medical Technology Association (AdvaMed) - Comment
Posted : 03/14/2012     ID :FDA-2011-D-0790-0017     Agency : FDA

Mar 09,2012 11:59 PM ET